PRTN3 and rheumatoid arthritis: In a large study based on two administrative claims databases in the United States, RF and ACPA positive RA patients had higher mortality rates compared to those lacking these antibodies, with significant differences in models adjusted for comorbidities, previous hospitalizations and current treatment [55].